Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

bioAffinity Technologies (BIAF) EBIT Margin (2022 - 2025)

Historic EBIT Margin for bioAffinity Technologies (BIAF) over the last 4 years, with Q3 2025 value amounting to 158.56%.

  • bioAffinity Technologies' EBIT Margin fell 745800.0% to 158.56% in Q3 2025 from the same period last year, while for Sep 2025 it was 153.2%, marking a year-over-year decrease of 640700.0%. This contributed to the annual value of 95.64% for FY2024, which is 2192000.0% up from last year.
  • bioAffinity Technologies' EBIT Margin amounted to 158.56% in Q3 2025, which was down 745800.0% from 198.16% recorded in Q2 2025.
  • bioAffinity Technologies' EBIT Margin's 5-year high stood at 80.84% during Q1 2024, with a 5-year trough of 169160.69% in Q1 2023.
  • For the 4-year period, bioAffinity Technologies' EBIT Margin averaged around 27600.56%, with its median value being 178.36% (2025).
  • Its EBIT Margin has fluctuated over the past 5 years, first soared by 1690798600bps in 2024, then plummeted by -1110800bps in 2025.
  • Quarter analysis of 4 years shows bioAffinity Technologies' EBIT Margin stood at 69213.17% in 2022, then skyrocketed by 100bps to 105.83% in 2023, then decreased by -26bps to 133.47% in 2024, then dropped by -19bps to 158.56% in 2025.
  • Its last three reported values are 158.56% in Q3 2025, 198.16% for Q2 2025, and 141.73% during Q1 2025.